Abstract RF02-03: Trastuzumab Deruxtecan (T-Dxd) in Combination with Anastrozole or Fulvestrant in Patients with HER2-low HR+ Advanced/metastatic Breast Cancer: a Phase 1b, Open-Label, Multicenter, Dose-Expansion Study (Destiny-Breast08)
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined